Evidence map›Paper›PMID 42438592›Full record

ArticleInternational journal of nanomedicine2026

MRI Monitored Mn-THPPmPEG12-Guided Phototherapy Elicits Abscopal Immunity and Synergizes with PD-1 Blockade in Triple-Negative Breast Cancer in Mice Model.

Le Bai, Mengjie Ma, Wenxia Yuan, Shaowei Bo, Zeyu Xiao, Dong Zhang, Xing Zhong, Junjie Zeng, Changzheng Shi, Liangping Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Dual metabolic checkpoint blockadeBioactive materials · 2027
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Le Bai *Department of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.ORCID 0009-0002-2456-7338
Mengjie Ma *Department of Minimally Invasive Interventional Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
Wenxia Yuan *Department of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Shaowei BoDepartment of Nuclear Medicine, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Zeyu XiaoDepartment of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0003-2220-5675
Dong ZhangDepartment of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0003-3657-0710
Xing ZhongDepartment of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Junjie ZengDepartment of Medical Imaging Center, The Fifth Affiliated Hospital of Jinan University, Heyuan, Guangdong, People's Republic of China.
Changzheng ShiDepartment of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.
Liangping LuoDepartment of Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, People's Republic of China.ORCID 0000-0002-7312-5782

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The study was to develop a clinical-translational theranostic photosensitizer, Mn-THPPmPEG12, for multiparametric MRI-monitored photodynamic therapy (PDT) of triple-negative breast cancer (TNBC), and to evaluate its potential to elicit abscopal immunity and synergize with PD-1 blockade. Methods: Mn-THPPmPEG12 was synthesized and characterized, and its MRI contrast capability was evaluated. A primary TNBC mouse model was established, and the PDT efficacy of Mn‑THPPmPEG12 was evaluated using intravoxel incoherent motion‑diffusion weighted imaging (IVIM‑DWI) and blood oxygen level‑dependent MRI (BOLD‑MRI), with final pathological analyses performed for validation. Subsequently, a bilateral TNBC mouse model was established to investigate the abscopal immune response in distant tumors following PDT of primary tumors, as well as the synergistic efficacy of combining PDT with anti‑PD‑1 blockade. Throughout the treatment, MRI served as a non-invasive method for real-time monitoring of therapeutic response. Results: Mn-THPPmPEG12 exhibited excellent water solubility and high T Conclusion: Mn-THPPmPEG12 serves as a potent theranostic platform that enables precise MRI-monitored PDT. The PDT mediated by Mn-THPPmPEG12 elicits an abscopal immune effect and synergizes with PD-1 blockade to enhance TNBC treatment.

Indexed as

Diffusion Magnetic Resonance ImagingMammary Neoplasms, ExperimentalPhotosensitizing AgentsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorContrast MediaDrug SynergismFemaleImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingMicePhotochemotherapyProgrammed Cell Death 1 ReceptorTheranostic NanomedicineContrast MediaImmune Checkpoint InhibitorsPhotosensitizing AgentsProgrammed Cell Death 1 Receptorimmune checkpoint inhibitorsmagnetic resonance imagingMn-THPPmPEG12photodynamic therapytriple-negative breast cancer

Identifiers

PMID42438592
PMCPMC13356842

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.